Dalpiciclib
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Dalpiciclib is a drug for the treatment of various forms of cancer. In China, dalpiciclib is approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed after previous endocrine therapy. Dalpicicilib is a CDK inhibitor that targets the CDK4 and CDK6 isoforms.
Dalpiciclib is a drug for the treatment of various forms of cancer. In China, dalpiciclib is approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed after previous endocrine therapy. Dalpicicilib is a CDK inhibitor that targets the CDK4 and CDK6 isoforms.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1357571692 under CC BY-SA 4.0; modifications have been made.